Archives des At-211 Publications

At-211 Publications, ATO-101™ publications

Atonco Receives ANSM Approval for the Performance Study of the Diagnostic Test Associated with the PERSEVERANCE EU Study

We are proud to announce that Atonco, as the sponsor, received ANSM authorization on August 20, 2026 to launch the performance study of its in vitro diagnostic medical device (IVD) as part of the PERSEVERANCE EU clinical trial. 🔬 A Key Test for Patient Selection This test, performed using immunohistochemistry in accordance with EU Regulation 2017/746, aims to detect the expression of CA-IX in order to select patients eligible for the PERSEVERANCE study. It is part of a precision medicine approach and paves the way for a future companion diagnostic (CDx) associated with targeted therapy. 🌍 A clinical first for…

14 September 2026

Read

At-211 Publications

Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5

Watabe, T.; Naka, S.; Shirakami, Y.; Kaneda, K.; Murakami, M.; Toyoshima, A.; Cardinale, J.; Giesel, F.L. Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5. Seminars in Nuclear Medicine 2025;55(6):947-954. DOI: 10.1053/j.semnuclmed.2025.09.005

27 November 2025

Read

At-211 Publications

First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)

Watabe, T.; Mukai, K.; Naka, S.; Sasaki, H.; Kamiya, T.; Hayakawa, T.; Fukuhara, A.; Takano, T.; Shirakami, Y.; Ooe, K.; Shigeno, S.; Okamura, S.; Masumura, K.; Hida, E.; Haba, H.; Toyoshima, A.; Isohashi, K.; Shimomura, I.; Tomiyama, N. First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). Journal of Nuclear Medicine 2025. – DOI: 10.2967/jnumed.125.270810

25 September 2025

Read

At-211 Publications

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

ClinicalTrials.gov ID: NCT03670966 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03670966

14 September 2018

Read

At-211 Publications

211At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

ClinicalTrials.gov ID: NCT03128034 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03128034

25 April 2017

Read

At-211 Publications

Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

Zalutsky, M.R.; Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; McLendon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6. Journal of Nuclear Medicine 2008;49(1):30-38. DOI: 10.2967/jnumed.107.046938

27 January 2008

Read